Overview

Gender

male

Robert Kamen is interim chief technology officer of Jounce Therapeutics and entrepreneur-in-residence of Third Rock Ventures. He joined Third Rock Ventures in 2010, bringing with him more than 30 years of experience in the pharmaceutical and biotechnology industries.

Most recently, he served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira®, the first fully human antibody to achieve marketing approval in the U.S. and Europe, and was a member of the Abbott Pharmaceuticals Executive Management Committee. Dr. Kamen also served as the president of BASF Bioresearch Corp. until it was acquired by Abbott Laboratories in 2001.

Earlier in his career, Dr. Kamen led discovery at Genetics Institute, Inc. In 2005, Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, acquired by Cephalon in 2010. Dr. Kamen serves as a director of Harbour Antibodies BV, Lycera Corp. and Opsonic Therapeutics, and advises other biopharmaceutical companies.Dr. Kamen holds an undergraduate degree in biophysics from Amherst College and a Ph.D. in biochemistry and molecular biology from Harvard University.